RVMDW - Revolution Medicines, Inc. Warrant Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

RVMDW

REVOLUTION MEDICINES, INC. WARRANT

NASDAQ

$9.76

▼ DOWN 5.20% (-0.54)

KEY STATISTICS

Market Cap$38.31 B

52w High$10.29

52w Low$0.39

Dividend Yield—

Frequency—

P/E-1.11

Volume63.66K

Shares Out.212.60M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Mark A. Goldsmith

COMPENSATION 2026

Salary$812,500

Stock Awards$3,968,076

Incentive Plan Pay$889,700

All Other Comp.$7,000

Total$14,672,390

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 13, 2020

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

883

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$19.44M

NOV

WED

PRICE

$9.76 ▼ DOWN 5.20% (−$0.54)

About Revolution Medicines, Inc. Warrant

https://www.revmed.com ↗

Revolution Medicines, Inc. is a clinical-stage biotech developing targeted RAS(ON) and companion inhibitors for precision oncology, with multiple candidates in various phases of clinical trials.

INDUSTRY

Biotechnology

A PRODUCT REVOLUTION MEDICINES, INC. WARRANT IS KNOWN FOR

Daraxonrasib (RMC-6236)

Daraxonrasib is an investigational oral RAS(ON) inhibitor by Revolution Medicines, in Phase 3 trials for cancers like pancreatic and lung, with FDA Breakthrough Therapy Designation for metastatic pancreatic cancer.